In the press

Chrysalis holds onto full Klarna stake after it secures $15.2bn valuation for IPO

Biotech trusts top performance charts in February

Eve Maddock-Jones, Investment Week,10 September 2025:

Chrysalis Investments has opted not to cash in on its Klarna investment as the buy-now-pay-later firm IPOs on the Nasdaq..

Matthew Read, head of production and senior research analyst at QuotedData, said that Chrysalis holding onto its shares makes sense given its prevailing 30% discount and the loans it has to repay.

“If it sold its entire stake in Klarna – there is no guarantee of this – that cash could have doubled,” Read said.

“Chrysalis has to repay its £70m loan, which would bring cash back to about £210m, but this compares to a market cap of £618m. Clearly, a 30% discount makes no sense given this.”

Read more here